Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.
about
Adoptive immunotherapy for cancer: building on successAdoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensHarnessing the Microbiome to Enhance Cancer ImmunotherapyCyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinomaCombined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccinationCD8+ T-cell memory in tumor immunology and immunotherapy.Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.Toll-like receptors in tumor immunotherapy.Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotypeImmunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsAdoptive T-cell transfer in cancer immunotherapy.Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanismsThe allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cellsDynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donor-Recipient Pairs.A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.Preimmunization of donor lymphocytes enhances antitumor immunity of autologous hematopoietic stem cell transplantation.Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.Immunocytokines: a review of molecules in clinical development for cancer therapy.Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.Adoptive immunotherapy for cancer.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Combinatorial immunotherapy for melanoma.In vivo delivery of interferon-α gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts.Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine.Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation.Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.Adoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion MedicineThe generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells.
P2860
Q24546258-691E0D4F-382E-420D-929C-D95E07F49EA4Q24644442-B84D48A0-86F5-4068-9E77-BC7B52EB3D3BQ28088598-1462751B-A128-45F8-908E-63BED821FB76Q33653210-8F0AF872-8B90-463B-877A-AF9BF17BD2E0Q33738279-84CABC0F-C637-4F44-A569-F2CF5560C888Q33760403-386F32F9-5B78-4461-84E8-5192B1E47859Q34426965-0F85209A-4C5C-4B5A-999B-1A3E5E6075AAQ34590434-D6874E66-81DA-47B7-A565-15C7D0BE8A8AQ34634616-637005D7-56C8-4464-9CEF-F9A1DC592927Q34703587-F0BB3767-A2F1-47ED-9A2E-D63F48FD3ED5Q34732473-0580D767-1EBE-45BC-BFA5-01264774636BQ34759603-EF980D67-B8C4-45DC-A51A-1042BFBF5561Q34768139-D15AE5D8-AA09-4305-A107-EDD1266E499FQ35162266-D2836C3E-F418-41EA-A868-9E8B3437B5DDQ35594089-28974BA0-42E4-4011-9A59-7155FDD640C0Q35638571-B8011683-C097-44E4-B83A-CC5F5C5D2082Q36253608-7DB962BA-F3BC-42BC-A0F4-CBE2FABAE719Q36340873-FBB05DB7-EBF1-4328-8EAD-E99FECB5427CQ36380188-BA6FB430-9F09-4AE3-BBBF-5BED216C3861Q36471818-FEBBD4E7-37A4-454B-BAAB-50F1F07A9CEBQ36585688-3AB02121-AF02-4BE5-9CF9-5651D87D4E1FQ36649570-27EE095F-96F3-49EC-A5BD-13A14EADC05DQ37114320-0C3CC3FF-A07A-4B27-8171-A75D84FFB94FQ37141237-3DF9D8A1-4563-40EC-8512-EFC2CA3B86C7Q37257207-5EF61E2C-1958-4D29-8A78-3788FCC9340EQ37482548-BB69DA5A-5093-483E-A292-AA2707E0C5ACQ37773301-95EC7038-8C57-4D3E-A37B-4F194E38A2BDQ38132742-59FF855F-A570-4B73-A9B6-E3A4DF9F181EQ38146713-F61A998D-05B6-49FD-94F9-2C186765ACA6Q38170496-85C9BAC6-18ED-4391-BB46-3225B76DD760Q38848219-D0555975-D038-4F44-BA87-59C9C4AE5CA2Q39005199-887D170E-5E8D-4C08-89F7-A4458564308BQ39536228-960096B1-7AE1-45B8-B33D-F2FB2B3DDA1EQ39679501-5AFFA3EE-FD99-450A-AB06-4F062DCD317FQ40167750-A1512C49-EF4A-4F1E-8BA6-B16D5D1F4869Q41577518-2C81B86F-B25F-455F-BCA2-F78F435F59A9Q42229717-F0356635-3111-40E8-9EA8-91D53FB557AAQ42783189-068925FD-F7CE-4FE3-A8FB-7C4CF9437EF7Q45037389-C8DC089F-33B7-4A08-A860-9B40D78C2382
P2860
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Less is more: lymphodepletion ...... ased anti-tumor immunotherapy.
@ast
Less is more: lymphodepletion ...... ased anti-tumor immunotherapy.
@en
type
label
Less is more: lymphodepletion ...... ased anti-tumor immunotherapy.
@ast
Less is more: lymphodepletion ...... ased anti-tumor immunotherapy.
@en
prefLabel
Less is more: lymphodepletion ...... ased anti-tumor immunotherapy.
@ast
Less is more: lymphodepletion ...... ased anti-tumor immunotherapy.
@en
P2860
P1476
Less is more: lymphodepletion ...... based anti-tumor immunotherapy
@en
P2093
Claudia Wrzesinski
P2860
P304
P356
10.1016/J.COI.2005.02.002
P577
2005-04-01T00:00:00Z